BiotechTube
EmeraMed

EmeraMed

Dublin, Ireland
emeramed.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

EmeraMed is a private, clinical-stage biotech developing Emeramide, a unique dithiol compound with antioxidant and metal-chelating properties. Its primary focus is on obtaining marketing authorization for treating mercury toxicity, supported by completed Phase 2 trials demonstrating safety. The company is also exploring applications in other conditions like COPD and COVID-19, where oxidative stress and iron dysregulation play a role, though these are in earlier stages of investigation.

Heavy Metal ToxicityCOPDInfectious Disease

Technology Platform

Emeramide (NBMI), a lipophilic, blood-brain-barrier penetrating dithiol compound that functions as both a heavy metal chelator (for mercury, lead, iron) and a direct antioxidant.

Opportunities

Orphan Drug Designations for mercury toxicity provide a accelerated regulatory pathway and market exclusivity.
The compound's unique safety profile and ability to cross the blood-brain barrier position it well in the underserved metal chelation and neuroprotection markets.
Broader applications in diseases driven by oxidative stress (e.g., neurodegenerative, inflammatory) represent a significant long-term expansion opportunity.

Risk Factors

Heavy reliance on a single compound with an unclear path to late-stage clinical trials and approval beyond initial Phase 2 data.
Active issue with counterfeit products being sold under its brand names, posing safety and reputational hazards.
The expansion into indications like COVID-19 is highly speculative and may lack strong clinical rationale.

Competitive Landscape

In heavy metal chelation, Emeramide competes with older, less specific agents like DMPS, DMSA, and EDTA, against which it claims a superior safety profile. In the broader antioxidant and mitochondrial therapeutic space, it faces competition from a wide range of preclinical and clinical compounds targeting oxidative stress in neurological, pulmonary, and metabolic diseases.

More companies in Small Molecule Drugs →More companies in Ireland →